Compare EDRY & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EDRY | MURA |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | Greece | Ireland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 36.0M |
| IPO Year | N/A | N/A |
| Metric | EDRY | MURA |
|---|---|---|
| Price | $13.06 | $2.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 3.2K | ★ 224.8K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,384,447.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.60 | $0.95 |
| 52 Week High | $16.14 | $4.74 |
| Indicator | EDRY | MURA |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 40.40 |
| Support Level | $12.94 | $2.06 |
| Resistance Level | $13.75 | $2.10 |
| Average True Range (ATR) | 0.27 | 0.01 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 45.34 | 25.00 |
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.